Skip to main content

Table 1 Baseline characteristics of all patients, stratified into quartiles of NT-pro CNP (pmol/L)

From: Elevated N-terminal pro C-type natriuretic peptide is associated with mortality in patients undergoing transcatheter aortic valve replacement

Variable

All (n = 309)

Q1 (n = 78)

Q2 (n = 77)

Q3 (n = 77)

Q4 (n = 77)

P value

NT-proCNP, min–max (pmol/L)

12.36–360.95

12.36–23.61

23.73–30.05

30.08–41.03

41.06–360.95

–

Age (years)

76.8 ± 6.3

76.3 ± 6.3

77.5 ± 5.4

76.9 ± 6.7

77.8 ± 7.2

0.20

Male sex

58.6 (181/309)

50.0 (39/78)

57.1 (44/77)

68.8 (53/77)

58.4 (45/77)

0.12

Body mass index (kg/m2)

22.6 ± 3.5

23.5 ± 3.7

23.0 ± 3.4

22.3 ± 3.1

21.8 ± 3.1

0.03

STS score

7.2 ± 5.7

6.0 ± 3.2

5.8 ± 3.0

7.5 ± 5.1

8.9 ± 6.4

0.001

TTE data

      

 Mean gradient, mm Hg

53.0 (42, 66)

52.5 (43, 67)

54.0 (41, 68)

53.0 (43, 66)

50.5 (38, 60)

0.23

 AVA, cm2

0.60 ± 0.24

0.64 ± 0.16

0.59 ± 0.19

0.63 ± 0.30

0.72 ± 0.42

0.37

 Maximum velocity, m/s

4.75 ± 0.84

4.72 ± 0.54

4.89 ± 0.68

4.87 ± 0.78

4.42 ± 0.83

0.42

 LVEF (%)

53.8 ± 13.6

56.1 ± 14.2

53.8 ± 12.5

52.1 ± 13.5

51.5 ± 14.7

0.05

HFpEF (%)

67.0 (207/309)

74.4 (58/78)

70.1 (54/77)

63.6 (49/77)

59.7 (46/77)

0.21

NYHA functional class

      

 III or IV

89.3 (276/309)

87.2 (68/78)

85.7 (66/77)

93.5 (72/77)

90.9 (70/77)

0.39

PVD

22.7 (70/309)

16.7 (13/78)

20.8 (16/77)

29.9 (23/77)

23.4 (18/77)

0.26

Prior PCI

12.9 (40/309)

10.3 (8/78)

10.4 (8/77)

13.0 (10/77)

18.2 (14/77)

0.42

Prior MI

1.6 (5/309)

0 (0/78)

2.6 (2/77)

1.3 (1/77)

2.6 (2/77)

0.52

Prior CABG

0.3 (1/309)

0 (0/78)

1.3 (1/77)

0 (0/77)

0 (0/77)

0.39

Prior stroke

5.5 (17/309)

3.8 (3/78)

7.8 (6/77)

3.9 (3/77)

6.5 (5/77)

0.63

Smoker

12.3 (38/309)

14.1 (11/78)

9.1 (7/77)

13.0 (10/77)

13.0 (10/77)

0.79

Hypertension

55.0 (170/309)

62.8 (49/78)

41.6 (32/77)

59.7 (46/77)

55.8 (43/77)

0.04

Dyslipidemia

23.3 (72/309)

25.6 (20/78)

20.8 (16/77)

22.1 (17/77)

24.7 (19/77)

0.88

Diabetes mellitus

22.0 (68/309)

24.4 (19/78)

22.1 (17/77)

18.2 (14/77)

23.4 (18/77)

0.80

COPD

22.7 (70/309)

25.6 (20/78)

19.5 (15/77)

23.4 (18/77)

22.1 (17/77)

0.83

NT-proBNP (pg/mL)

2837 (991–8533)

367 (204–742)

1822 (1361–2494)

5178 (3808–6543)

17,427 (12,420–26,013)

 < 0.001

Creatinine (μmol/L)

96.9 ± 84.4

70.2 ± 17.2

80.7 ± 18.7

92.0 ± 29.2

125.0 ± 100.2

 < 0.001

eGFR (mL/min/1.73m2)

70.7 ± 22.9

82.7 ± 16.2

75.6 ± 16.8

68.8 ± 20.4

56.7 ± 24.5

 < 0.001

  1. NT-proCNP, N-terminal pro C-type natriuretic peptide; STS, Society of Thoracic Surgeons; TTE, transthoracic echocardiography; AVA, aortic valve area; LVEF, left ventricular ejection fraction; HFpEF, heart failure with preserved EF; PVD, peripheral vascular disease; PCI, percutaneous coronary intervention; MI, myocardial infarction; CABG, coronary artery bypass grafting; COPD, chronic obstructive pulmonary disease; NT-proBNP, N-terminal pro B-type natriuretic peptide; eGFR, estimated glomerular filtration rate
Back to article page

BMC Cardiovascular Disorders

ISSN: 1471-2261

Contact us